Australia markets close in 49 minutes

Fennec Pharmaceuticals Inc. (FENC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.18+0.04 (+0.44%)
At close: 04:00PM EDT
9.18 0.00 (0.00%)
After hours: 04:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 249.43M
Enterprise value 267.12M
Trailing P/E N/A
Forward P/E 29.59
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.47
Price/book (mrq)84.82
Enterprise value/revenue 12.57
Enterprise value/EBITDA -21.60

Trading information

Stock price history

Beta (5Y monthly) 0.40
52-week change 311.34%
S&P500 52-week change 323.10%
52-week high 311.92
52-week low 36.30
50-day moving average 310.02
200-day moving average 38.95

Share statistics

Avg vol (3-month) 3135.78k
Avg vol (10-day) 3160.15k
Shares outstanding 527.1M
Implied shares outstanding 627.19M
Float 815.29M
% held by insiders 114.60%
% held by institutions 155.25%
Shares short (15 Apr 2024) 41.87M
Short ratio (15 Apr 2024) 411.45
Short % of float (15 Apr 2024) 49.78%
Short % of shares outstanding (15 Apr 2024) 46.91%
Shares short (prior month 15 Mar 2024) 41.69M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -75.50%
Operating margin (ttm)-18.67%

Management effectiveness

Return on assets (ttm)-29.67%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)21.25M
Revenue per share (ttm)0.80
Quarterly revenue growth (yoy)534.20%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-16.05M
Diluted EPS (ttm)-0.60
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.27M
Total cash per share (mrq)0.49
Total debt (mrq)30.95M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.56
Book value per share (mrq)-0.43

Cash flow statement

Operating cash flow (ttm)-17.14M
Levered free cash flow (ttm)-12.35M